000			02005 a2200541 4500
005			20250515055226.0
264		0	_c20070216
008			200702s 0 0 eng d
022			_a1476-4687
024	7		_a10.1038/nature05506 _2doi
040			_aNLM _beng _cNLM
100	1		_aKreitzer, Anatol C
245	0	0	_aEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. _h[electronic resource]
260			_bNature _cFeb 2007
300			_a643-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aBenzamides _xpharmacology
650	0	4	_aBenzoxazines
650	0	4	_aCannabinoid Receptor Modulators _xmetabolism
650	0	4	_aCarbamates _xpharmacology
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xdeficiency
650	0	4	_aDopamine D2 Receptor Antagonists
650	0	4	_aEndocannabinoids
650	0	4	_aExcitatory Postsynaptic Potentials _xdrug effects
650	0	4	_aIn Vitro Techniques
650	0	4	_aLong-Term Synaptic Depression _xdrug effects
650	0	4	_aMice
650	0	4	_aMice, Transgenic
650	0	4	_aMorpholines _xpharmacology
650	0	4	_aNaphthalenes _xpharmacology
650	0	4	_aNeostriatum _xcytology
650	0	4	_aNeuronal Plasticity _xphysiology
650	0	4	_aOxidopamine _xpharmacology
650	0	4	_aParkinson Disease _xmetabolism
650	0	4	_aPiperidines _xpharmacology
650	0	4	_aPsychomotor Performance _xphysiology
650	0	4	_aPyrazoles _xpharmacology
650	0	4	_aReceptor, Cannabinoid, CB1 _xmetabolism
650	0	4	_aReceptors, Dopamine D2 _xagonists
650	0	4	_aReceptors, N-Methyl-D-Aspartate _xmetabolism
650	0	4	_aReserpine _xpharmacology
650	0	4	_aSynapses _xdrug effects
700	1		_aMalenka, Robert C
773	0		_tNature _gvol. 445 _gno. 7128 _gp. 643-7
856	4	0	_uhttps://doi.org/10.1038/nature05506 _zAvailable from publisher's website
999			_c16848075 _d16848075